Krystal Biotech Holds Annual Stockholders Meeting

Krystal Biotech ( (KRYS) ) has issued an announcement.

On May 16, 2025, Krystal Biotech held its Annual Meeting of Stockholders where key decisions were made, including the election of Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for 2025. Additionally, stockholders approved the compensation of the company’s named executive officers for the fiscal year 2024, reflecting confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Spark’s Take on KRYS Stock

According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.

Krystal Biotech’s strong financial performance and strategic growth initiatives are significant strengths, highlighted by revenue growth and European market expansion. However, technical indicators and high valuation present notable risks. The company’s ability to manage operational challenges and sustain growth will be crucial in influencing future stock performance.

To see Spark’s full report on KRYS stock, click here.

More about Krystal Biotech

Krystal Biotech, Inc. operates in the biotechnology industry, focusing on developing and commercializing novel treatments for dermatological diseases using gene therapy.

Average Trading Volume: 337,665

Technical Sentiment Signal: Sell

Current Market Cap: $3.77B

For detailed information about KRYS stock, go to TipRanks’ Stock Analysis page.